公司資料
Humacyte 股價、新聞與催化劑
- 股票代碼:
- HUMA
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
0.64 USD (-5.75%)
收盤價
最後更新: 2026年8月21日
309M USD
市值
股價為何變動
The latest monitored company update is “Humacyte Confirms Plans for ATEV Supplemental BLA Filing for Dialysis Access Following FDA Discussions.” The corresponding closing-price reaction is not yet available.
公司概覽
Bioengineered Human Tissue Platform
Humacyte develops implantable vascular conduits manufactured from human vascular cells and designed to become repopulated by the patient's own cells. The platform is intended to produce universally implantable tissues at commercial scale.
SYMVESS
SYMVESS is an FDA-approved acellular tissue-engineered vessel for urgent arterial repair after extremity vascular trauma. It is Humacyte's first commercial product and validates the broader tissue platform.
Hemodialysis Access
The Phase 3 V012 study compared the vessel with autologous arteriovenous fistulas for hemodialysis access in women. Positive results form the basis for a planned supplemental BLA.
Coronary Program
Humacyte's coronary tissue-engineered vessel is being developed as an off-the-shelf conduit for coronary artery bypass grafting. The FDA has cleared the IND for a first-in-human Phase 2a study.
Broader Vascular Applications
Additional development areas include peripheral artery disease, pediatric heart surgery, type 1 diabetes, and other cell and tissue applications.
未來催化劑
- Initiation of a Phase 2a study of the coronary tissue-engineered vessel in coronary artery bypass grafting in the third quarter of 2026.
- Submission of a supplemental BLA for the acellular tissue-engineered vessel in hemodialysis access in the second half of 2026.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。